Case report

Acute undifferentiated leukemia limited to neck lymph nodes and a large mediastinal mass

Kenta Hayashino,1) Masayuki Matsuda,1) Keigo Fujishita,1) Jun Iwata,2) Miki Mizobuchi,3) Munenori Uemura,3) Kenji Yorita,4) Akiko Maeshima,5) Toshi Imai1)

In the 2016 update of the World Health Organization (WHO) classification of myeloid neoplasms, acute undifferentiated leukemia (AUL) was defined by a lack of lineage-specific markers. AUL has very poor prognosis and no established therapies due to its rarity. We report a case of a 31-year-old man with AUL who showed complete molecular response to an acute lymphoblastic leukemia (ALL)-based regimen and received allogeneic hematopoietic stem cell transplantation. The patient’s blast cells were CD7-positive and localized to lymph nodes in the neck and to a large mediastinal mass; there was also rearrangement of the T-cell receptor delta locus. Although the tumor showed characteristics of T-cell lymphoblastic lymphoma, it was categorized as AUL based on WHO classification. This case suggests that a high-intensity conditioning regimen could be effective for rare cases of AUL that present only in the extramedullary mass, and chemotherapy for AUL should be selected based on the characteristics of the blasts.

Keywords: acute undifferentiated leukemia, rare leukemia, allogeneic hematopoietic stem cell transplantation, conditioning regimen

INTRODUCTION

In the 2016 update of the World Health Organization (WHO) classification of myeloid neoplasms, acute leukemias of ambiguous lineage (ALAL) are a rare subtype of acute leukemia that lack evidence of myeloid or lymphoid lineage or show evidence of more than one lineage. Acute undifferentiated leukemia (AUL) is listed as a subcategory of ALAL, which lacks the major immunophenotypic lineage markers including myeloperoxidase (MPO), cCD3, CD19, cCD22, and CD79a, and usually expresses only one surface lineage marker such as CD13, CD33, and CD7. Furthermore, due to its immature characteristics, AUL commonly expresses stem cell markers including CD34, HLA-DR, and terminal deoxynucleotidyl transferase (TdT).1-3

Because of the rarity of AUL, an optimal treatment strategy has not yet been established. Some clinicians suggest treating AUL with acute myeloid leukemia (AML)-based regimens because AUL sometimes has genetic and cytokinetic mutations observed in AML, such as IDH1 mutations del5q, del7, and del17p.4,5 In contrast, other clinicians suggest treating AUL with an acute lymphoblastic leukemia (ALL)-based regimen, which is effective for mixed phenotype acute leukemia (MPAL), which is also classified as ALAL.2,6,7 No firm conclusion has been reached over which induction and consolidation chemotherapy - an AML-based regimen or an ALL-based regimen - should be administered to patients with AUL. On the other hand, most of clinicians agree the necessity of receiving allogeneic hematopoietic stem cell transplantation (Allo-HSCT) to achieve long-term survival because of their poor prognosis.6,8 However, AUL occurs in older patients compared to AML and ALL, and most of the patients cannot be treated with chemotherapy.9

Herein, we report a rare case of AUL in a young patient who presented with abnormal lymphocytes only in lymph nodes of the neck and in a large mediastinal mass, thus resembling a T-lymphoblastic lymphoma (T-LBL). The patient achieved complete molecular response to an ALL-based regimen and underwent Allo-HSCT.
CASE

A 31-year-old man presented to the Japanese Red Cross Kochi Hospital with breathing difficulties. Chest radiography revealed a large mediastinal mass and positron emission tomography-computed tomography (PET-CT) showed high fluorodeoxyglucose accumulation in the mediastinal mass and multiple neck lymph nodes (SUVmax 13.9) (Fig. 1). Neck lymph node biopsies showed that the mass consisted of medium to large lymphocyte-like blast cells. Immunohistochemical staining revealed that the blast cells were positive for CD7, CD34, and CD99(dim), and negative for CD1a, CD3 (clone F7.2.38), CD4, CD5, CD8, CD10, CD15, CD20, CD30, CD56, CD79a, CD117, TdT, anaplastic lymphoma kinase (ALK), and myeloperoxidase (MPO) (Fig. 2). The blast cells were negative for Epstein-Barr virus-encoded small RNA (EBER) by in situ hybridization. Flow cytometric analysis of cells from the lymph nodes confirmed expression of CD7, CD34, and HLA-DR. The blasts did not express CD2, CD3, CD5, CD8, CD10, CD14, CD19, CD20, CD22, CD56, KORSA, and MPO (Fig. 3). The results of conventional G-banding chromosomal analysis of the lymph node revealed 92, XXYY, del(5)(q22q31)×2, add(6)(p21.3)×2, add(7)(p15)×2, t(9;15)(p13;q11.2)×2, i(17)(q10)×2 [20/20]. The peripheral blood film and bone marrow aspirate demonstrated no evidence of blast cells. Because the blast cells were not positive for any lineage-specific markers, the patient was diagnosed with AUL based on the 2016 updated WHO classification of hematological malignancies. He was initially treated with induction therapy usually used for AML patients (idarubicin 12 mg/m² for 3 days and cytarabine 100 mg/m² for 7 days). However, due to a rearrangement in the T cell receptor (TCR) delta locus detected after two days, the therapy was changed to an ALL-based induction therapy (cyclophosphamide 1000 mg/m² for 1 day, daunorubicin 50 mg/m² for 1 days, vincristine 2 mg for 4 days, L-asparaginase 6000 U/m² for 6 days, and prednisolone 100 mg for 21 days).

After induction therapy, the patient was transferred to Kochi health sciences center for further evaluation and man-

---

Fig. 1. Positron emission tomography-computed tomography (PET-CT) scan of neck lymph nodes and a large mediastinal mass (SUVmax 13.9).

Fig. 2. Analysis of neck lymph node biopsy by Hematoxylin-Eosin (HE) staining and CD7, CD34, CD99, CD1a, CD3, CD4, CD8, MPO, and TdT immunohistochemistry.
agement of the acute leukemia. PET-CT revealed no accumu-
lation, and peripheral blood film and bone marrow aspirate also showed absence of blast cells. Based on these 
findings, he was in complete remission and we assumed that 
the ALL-based therapy was effective. Next, the patient 
started receiving ALL-based consolidation therapy. After 
two course of consolidation therapies, the patient maintained 
complete molecular response, and underwent allogeneic 
peripheral blood stem cell transplantation from an HLA fully 
matched brother. The conditioning regimen was medium-
dose etoposide (ETP, 15 mg/kg for 2 days), high-dose cyclo-
phosphamide (CY, 60 mg/kg for 2 days), and total body irra-
diation (TBI, 12 Gy in 6 fractions). Graft versus host 
disease (GVHD) prophylaxis consisted of cyclosporine (3 
mg/kg/day from day-1), short-term methotrexate (10 mg/m^2 
day 1, 7 mg/m^2 day 3, 6), and anti-thymocyte globulin (1 mg/
kg for 2 days). Regimen-related toxicities and grade 1 acute 
skin GVHD were controllable. Neutrophil engraftment 
occurring on day 12, full donor chimerism was established on 
day 27, and he was discharged on day 56. Currently, he 
maintains remission more than 9 months from transplantation.

**DISCUSSION**

AUL is a very rare leukemia with poor prognosis and no
established treatment. In this case, the blast cells were posi-
tive for CD34, HLA-DR, and CD7, which are usually 
observed in AUL. However, the blast cells formed a 
large mediastinal mass and showed rearrangement of the 
TCR delta locus. In addition, the blast cells were slightly 
good for CD99. CD99 is expressed in both immature 
myeloid-lineage and B-lineage cells, but immature thymic 
T-lineage cell shows highest levels of expression. Although 
our patient was diagnosed with AUL on the basis of the 2016 WHO classification, the blast cells had similar 
characteristics to T-LBL. Based on the clinical characteris-
tics, he was treated with an ALL-based regimen, and 
achieved complete remission. Furthermore, he underwent 
allogeneic peripheral blood stem cell transplantation using a 
high intensity conditioning regimen which is an effective regi-
men for high risk ALL, and he maintains remission.

Since the 2008 WHO classification, MPO, cCD3, CD19, 
cCD22, and CD79a are defined as lineage markers. Before 
the revision of the classification, some cases of leukemia, 
which were only positive for CD7 and had no lineage mark-
ers like this case were reported; they were called CD7-
positive stem cell leukemia. CD7-positive stem cell leukemia 
frequently exhibit bone marrow invasion, mediastinal 
masses, and lymphadenopathy. These leukemias are charac-
terized by rearrangements of the TCR or immunoglobulin 
heavy chain and show at relapse myeloid or lymphoid lin-
eges. Like AUL, CD7-positive stem cell leukemia is con-
sidered to originate from pluripotent hematopoietic stem 
cells based on the evidence that CD7-positive/CD4/8-negative 
blast cells have the ability to differentiate into myeloid and 
lymphoid lineages. In the presented case, we presumed 
that the blast cells originated from pluripotent hematopoietic 
stem cells prior to the prothymocyte stage because of the lack 
of CD3 which is usually observed in the process of differenti-
ation into prothymocytes.

Chromosomal analysis from the patient’s G-banding pat-
terns revealed the presence of tetraploidy (92, XXYY). One 
report suggested that chromosome abnormalities are a poor 
prognostic factor for AUL. In that report, five in ten patients 
of AUL had chromosomal abnormalities, and all of these 
patients experienced primary induction failure. Three 
patients could not achieve complete response until HSCT and 
two patients experienced relapse post-HSCT (the others died 
as a result of sepsis or acute respiratory distress syndrome). In 
addition, there are case reports that AUL with near tetra-
ploidy was resistant to induction and re-induction therapy. 
Similarly for AML, in one trial, less than half of near-tetra-
ploid patients (11 of 23 cases) showed a complete response to induction therapy. In contrast to AUL and AML, near-tetraploidy is a favorable prognostic factor for childhood ALL. As already mentioned above, our case had characteristics of T cell lineage, and did not have poor prognostic chromosome abnormalities such as −7, −5, t(9;22), t(4;11), and t(1;19). These factors could have contributed to a favorable response to treatment.

Our patient was treated with conventional conditioning regimen (CY and TBI) plus medium-dose ETP. This conditioning regimen adding medium-dose ETP is known to decrease the rate of ALL relapse. Considering his general medical condition and the risk of recurrence, we selected this high-intensity conditioning regimen. He has been well without relapse since Allo-HSCT.

In conclusion, we report a rare case of AUL localized to the neck lymph nodes and a large mediastinal mass. The patient showed complete response to an ALL-based regimen and received Allo-HSCT. This case suggests that chemotherapy for AUL should be selected based on the characteristics of the blast cells. More data are needed to understand the mechanism, pathogenesis, and best treatment, including targeted therapy for AUL.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

ACKNOWLEDGMENTS

The authors would like to thank the patient and medical staff for their contributions to this case report.

ETHICAL PUBLICATION STATEMENT

We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. This study was approved by the research ethics committee of the Kochi Health Sciences Center and had consent from patient.

REFERENCES